BBP vs. CANC
Compare and contrast key facts about Virtus LifeSci Biotech Products ETF (BBP) and Tema Oncology ETF (CANC).
BBP and CANC are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. BBP is a passively managed fund by Virtus Investment Partners that tracks the performance of the LifeSci Biotechnology Products Index. It was launched on Dec 17, 2014. CANC is an actively managed fund by Tema. It was launched on Aug 14, 2023.
Performance
BBP vs. CANC - Performance Comparison
Loading graphics...
BBP vs. CANC - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
BBP Virtus LifeSci Biotech Products ETF | 3.94% | 33.15% | 3.32% | 17.88% | 0.85% | -4.00% |
CANC Tema Oncology ETF | 5.69% | 42.92% | -5.37% | 510.51% | -85.34% | -51.82% |
Returns By Period
In the year-to-date period, BBP achieves a 3.94% return, which is significantly lower than CANC's 5.69% return.
BBP
- 1D
- 5.93%
- 1M
- -2.16%
- YTD
- 3.94%
- 6M
- 18.71%
- 1Y
- 41.70%
- 3Y*
- 19.01%
- 5Y*
- 9.37%
- 10Y*
- 12.76%
CANC
- 1D
- 4.66%
- 1M
- -2.88%
- YTD
- 5.69%
- 6M
- 27.93%
- 1Y
- 52.46%
- 3Y*
- 140.00%
- 5Y*
- —
- 10Y*
- —
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
BBP vs. CANC - Expense Ratio Comparison
BBP has a 0.79% expense ratio, which is higher than CANC's 0.75% expense ratio.
Return for Risk
BBP vs. CANC — Risk / Return Rank
BBP
CANC
BBP vs. CANC - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Virtus LifeSci Biotech Products ETF (BBP) and Tema Oncology ETF (CANC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| BBP | CANC | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.55 | 1.94 | -0.39 |
Sortino ratioReturn per unit of downside risk | 2.18 | 2.59 | -0.41 |
Omega ratioGain probability vs. loss probability | 1.27 | 1.32 | -0.06 |
Calmar ratioReturn relative to maximum drawdown | 2.69 | 3.86 | -1.17 |
Martin ratioReturn relative to average drawdown | 10.18 | 13.76 | -3.58 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| BBP | CANC | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.55 | 1.94 | -0.39 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.36 | — | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.47 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.39 | -0.04 | +0.43 |
Correlation
The correlation between BBP and CANC is 0.52, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Dividends
BBP vs. CANC - Dividend Comparison
BBP has not paid dividends to shareholders, while CANC's dividend yield for the trailing twelve months is around 0.05%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BBP Virtus LifeSci Biotech Products ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.18% | 0.00% | 1.29% |
CANC Tema Oncology ETF | 0.05% | 0.06% | 3.00% | 0.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
BBP vs. CANC - Drawdown Comparison
The maximum BBP drawdown since its inception was -44.32%, smaller than the maximum CANC drawdown of -97.53%. Use the drawdown chart below to compare losses from any high point for BBP and CANC.
Loading graphics...
Drawdown Indicators
| BBP | CANC | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -44.32% | -97.53% | +53.21% |
Max Drawdown (1Y)Largest decline over 1 year | -13.38% | -12.40% | -0.98% |
Max Drawdown (5Y)Largest decline over 5 years | -38.28% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -44.32% | — | — |
Current DrawdownCurrent decline from peak | -3.90% | -56.19% | +52.29% |
Average DrawdownAverage peak-to-trough decline | -12.16% | -73.91% | +61.75% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.72% | 3.61% | +0.11% |
Volatility
BBP vs. CANC - Volatility Comparison
Virtus LifeSci Biotech Products ETF (BBP) has a higher volatility of 11.21% compared to Tema Oncology ETF (CANC) at 8.36%. This indicates that BBP's price experiences larger fluctuations and is considered to be riskier than CANC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| BBP | CANC | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 11.21% | 8.36% | +2.85% |
Volatility (6M)Calculated over the trailing 6-month period | 18.03% | 16.34% | +1.69% |
Volatility (1Y)Calculated over the trailing 1-year period | 27.16% | 27.24% | -0.08% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 26.23% | 285.66% | -259.43% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 27.51% | 285.66% | -258.15% |